Science & Health
A Growing Body of Evidence, and Its Limits
Chronic pain affects an estimated one in five adults across Europe, and for years cannabis has occupied an awkward space in clinical conversations — anecdotally common, scientifically underexplored, and legally fraught. That picture is slowly changing. A growing body of peer-reviewed research is now examining cannabinoids — primarily THC, CBD, and their combinations — with more rigour than was possible a decade ago, and the findings are nuanced enough to merit careful attention from both clinicians and policymakers.
The emerging consensus is cautiously supportive for specific pain types. Evidence is strongest for neuropathic pain — nerve-related discomfort associated with conditions such as multiple sclerosis, diabetes, and chemotherapy — where several controlled trials have found modest but statistically significant improvements in pain scores compared to placebo. For musculoskeletal and inflammatory pain, the picture is less clear. Studies show variable outcomes depending on dosage, route of administration, cannabinoid ratios, and individual patient factors including genetics and prior cannabis exposure.
What remains consistent across recent literature is the acknowledgement of side-effect profiles. Dizziness, sedation, cognitive disturbance, and — with chronic high-THC use — dependence risk are documented concerns. Researchers and clinicians are increasingly emphasising that cannabis for pain is not a risk-free alternative, but a clinical option that requires the same careful benefit-risk assessment as any other analgesic.
The Route of Administration Question
One area where the science has become notably more specific is in how cannabinoids are delivered. Inhaled cannabis produces faster onset but less predictable dosing; oral and sublingual formats offer more consistent bioavailability but slower effect. Pharmaceutical-grade cannabis-based medicines — standardised extracts with known THC and CBD concentrations — are increasingly favoured in clinical settings precisely because they allow the kind of dosing control that research and responsible prescribing require.
This distinction matters in a Maltese context. The legal framework governing cannabis here separates recreational association-based use — managed through licensed Cannabis Harm Reduction Associations (CHRAs) under the Authority on the Responsible Use of Cannabis (ARUC) — from medicinal cannabis, which operates under a separate regulatory and prescribing pathway. Patients seeking cannabis specifically for pain management are, in principle, better served through the medicinal route, where a physician can evaluate appropriateness, monitor outcomes, and adjust treatment.
What This Means for Malta's CHRAs and ARUC
The clinical nuance in the latest research creates a practical challenge for Malta's CHRAs. These associations exist to provide a regulated, harm-reduction-oriented environment for adult recreational use — they are not clinics, and their members are not patients by definition. Yet in any population of cannabis users, some proportion will be using cannabis at least partly to manage pain, whether or not they have a formal diagnosis or prescription.
This is not unique to Malta. Across Europe, harm reduction organisations report that self-medication for chronic pain is among the most commonly cited reasons members give for cannabis use. The question for ARUC and for CHRAs themselves is how to handle that reality responsibly — ensuring members are aware of formal medicinal pathways, without overstepping into clinical territory that CHRAs are not authorised or equipped to occupy.
The science does not suggest that recreational cannabis and medicinal cannabis serve the same function for pain. The dosing, the products, the monitoring, and the clinical oversight are different. Both can coexist in a regulated system, but they should not be conflated.
Healthcare professionals working in Malta — GPs, neurologists, pain specialists — are in a position to benefit from the clearer clinical picture that current research provides. Several European countries, including Germany following its recent reforms and the Netherlands through its longstanding medicinal programme, have developed prescribing guidelines that Maltese clinicians can look to as reference points, even where local guidance remains limited.
The Gaps That Still Exist
It would be misleading to suggest the science is settled. Long-term studies remain scarce; most trials run for weeks or months, not years. Research on older adults — a population with high rates of chronic pain and also higher vulnerability to cannabis-related adverse effects — is particularly thin. And there is a persistent gap between the pharmaceutical-grade products used in trials and the variable cannabis available through informal or even association-based channels, making direct translation difficult.
For Maltese patients, the practical takeaway is straightforward: if pain management is the goal, the medicinal pathway — with a prescribing physician, standardised product, and clinical follow-up — remains the most evidence-aligned option. For ARUC and policymakers, the evolving evidence base is a prompt to ensure that the boundary between recreational and medicinal frameworks remains clear, well-communicated, and easy for both clinicians and patients to navigate.
The science on cannabis and pain is maturing. Malta's regulatory architecture, still relatively young, has the opportunity to mature alongside it.
Sources
MedCentral
Featured image: Photo by Fatih Ustaosmanoğlu on Pexels
Members Discussion